Landogrozumab – Kodiac biolabs

Plain-language summaryIntrigue 48 / 100

Landogrozumab (LY2495655) is Eli Lilly’s anti-myostatin antibody, built as an IgG4 isotype to reduce immune effector function compared to the IgG1 antibodies in the class. Phase 2 trials targeted cancer cachexia, hip-fracture-associated muscle wasting, and elective total hip arthroplasty recovery, all populations where preserving lean mass might affect functional outcomes. The trials produced muscle mass increases but limited functional benefit, echoing the pattern seen across the entire myostatin-blocking class. The program was discontinued. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

40/100

Phase 2-stalled anti-myostatin mAb with real mass signal but inconsistent functional translation

Look, the anti-myostatin story is old enough to have a college degree. McPherron’s 1997 knockout mice, the early Wyeth antibody programs, Pfizer’s domagrozumab stumbling in Duchenne — the field has been trying to turn myostatin inhibition into a clinical win for a long time, and the wins keep coming out smaller than hoped. Landogrozumab doesn’t escape that pattern.

What Lilly did right is the isotype choice. IgG4 instead of IgG1 means substantially less Fc receptor engagement and complement activation, which matters a lot when you’re talking about chronic dosing in a frail or immunocompromised population. That’s not just a packaging detail; it reduces one of the real confounds in interpreting antibody studies. For any investigator who wants to neutralize myostatin cleanly without layering in Fc-mediated biology, that IgG4 format is genuinely useful.

The phase 2 data tells a complicated story. Trials in cancer cachexia, hip-fracture-associated sarcopenia, and statin-associated myopathy all showed real muscle mass increases — roughly 4 percent at six months, which is statistically detectable and mechanistically consistent. The problem is functional outcomes. Grip strength, walking speed, functional independence scores… inconsistent across the board. This is, honestly, the central unresolved question of the entire myostatin inhibition class. You can grow the muscle, but does that muscle do anything? The answer so far is: sometimes, not reliably. Development never advanced to phase 3, which tells you what Lilly concluded.

We think the comparison to bimagrumab is important context here. Bimagrumab targets ActRIIB directly, capturing not just myostatin but activin A and other ligands — that broader inhibition profile seems to produce more meaningful functional signals in some populations, particularly when combined with caloric restriction. Landogrozumab’s narrower myostatin-specific approach means cleaner mechanistic attribution in a research setting, but it also means you’re probably leaving efficacy on the table if the goal is actual functional improvement.

For bench use, the compound has a real niche. Investigators studying myostatin signaling, cachexia biology, or muscle fiber hypertrophy mechanisms have a validated, well-characterized tool here. The reduced effector function matters for clean readouts. Thats not nothing. But the clinical development story is a ceiling, not a floor, and anyone building a research program around this class needs to account for the mass-without-function problem thats defined every anti-myostatin program so far.

Novelty: 32
Mechanism promise: 42
In-category differentiation: 30
Evidence quality: 52
Translational signal: 38
Research bench value: 58

Rationale Scored down on novelty and differentiation because the anti-myostatin antibody class is 20+ years old and functionally outcompeted by ActRII-targeting approaches like bimagrumab; bench value is the relative bright spot because the IgG4 isotype makes it a clean myostatin probe with reduced Fc confounding for muscle biology studies. Evidence quality reflects real Lilly-backed phase 2 trials across three indications, but the mass-without-function pattern and halted development cap translational enthusiasm.

Anti-myostatin monoclonal antibody

A humanized anti-myostatin monoclonal antibody developed at Eli Lilly; investigated for cancer cachexia and muscle wasting.

Abstract

Landogrozumab (LY2495655; humanized IgG4 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Eli Lilly. The IgG4 isotype reduces effector function (Fc receptor engagement, complement activation) compared to IgG1, theoretically reducing immunogenicity for chronic dosing. Phase 2 trials in cancer cachexia, hip-fracture-associated muscle loss, and statin-associated muscle pain demonstrated muscle mass increases of approximately 4 percent at 6 months but inconsistent functional improvement. Development has not advanced to phase 3. Used as a research compound for selective myostatin neutralization with reduced effector function.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-362Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.